Not provided
Not provided
Not provided
Not provided
Not provided
Failed to pass the Ministry of Science and Technology.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the impact of Duloxetine and Imipramine on therapeutic efficacy, psychological distress, sexual function, bladder wall structure and blood flow in women
To assess the impact of Duloxetine and Imipramine on therapeutic efficacy, psychological distress, sexual function, bladder wall structure and blood flow in women
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Duloxetine | Experimental | Receive Duloxetine 30 mg treatment per day |
|
| Imipramine | Active Comparator | Receive Imipramine 25 mg treatment per day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Duloxetine | Drug | Duloxetine 30 mg qd |
| |
| Imipramine |
| Measure | Description | Time Frame |
|---|---|---|
| the score of International Consultation on Incontinence Questionnaire-Urinary Incontinence | Between-group difference in the score of International Consultation on Incontinence Questionnaire-Urinary Incontinence | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| the score of Urgency Severity Scale | Between-group difference in the score of Urgency Severity Scale | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| the score of Overactive Bladder Symptom Score | Between-group difference in the score of Overactive Bladder Symptom Score | 8 weeks |
| the score of King's health questionnaires | Between-group difference in the score of King's health questionnaires |
Inclusion Criteria:
- Stress urinary incontinence
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital | Banqiao District | New Taipei | 22050 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Imipramine 25mg qd |
|
| 8 weeks |
| the score of Brief symptom rating scale | Between-group difference in the score of Brief symptom rating scale | 8 weeks |
| the score of Female sexual function index | Between-group difference in the score of Female sexual function index | 8 weeks |
| Blood flow index of the bladder | Between-group difference in the changes of blood flow index of the bladder | 8 weeks |
| Bladder wall thickness | Between-group difference in the changes of Bladder wall thickness | 8 weeks |
| ID | Term |
|---|---|
| D014550 | Urinary Incontinence, Stress |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068736 | Duloxetine Hydrochloride |
| D007099 | Imipramine |
| ID | Term |
|---|---|
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D003984 | Dibenzazepines |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided